【24h】

Reply

机译:回复

获取原文
获取原文并翻译 | 示例
           

摘要

We thank Dr. Donas and Dr. Wisselink for their comments on our article and do appreciate Dr. Donas' efforts to defend the chimney technique. It would be wrong to go into a battle over details regarding inclusion of articles in reviews, statistics, or even their last article. Reviews are always prone to several inclusion biases, mainly to avoid double inclusion of patients. In their own latest pooled analysis, they included two of our studies with some overlapping patient cohorts. With regard to the statistical analysis, one could find support in the literature for every single method. Other authors as well have previously used the Fisher exact test for a similar type of comparison. Far more important to the reader is to remain critical about any new technique before adopting it in a large proportion of patients. In an expert center such as Munster, there is no doubt that all treatment options (open surgery, fenestrated stent-graft, and chimney technique) are carefully balanced before choosing the most appropriate option for each individual patient. It is the ethical task of each expert center, however, to underline in every presentation and publication that patients treated with chimneys were carefully selected or that no other treatment options seemed more suited. We congratulate Donas et al. for their recent series demonstrating durability of Ch-EVAR at 24-month follow-up. We would like to point out, however, that Munster uses the fenestrated technique for more complex cases (i.e., more than 1 to 2 chimneys required) and that the 40 patients studied in the aforementioned article represented only 32% of the total patients treated in the 3-year observation period. As elaborated by Dr. Wisselink in his invited comment, the longer-term outcome of "gutter" type I endoleaks, especially in cases where progression of aneurysmal disease (i.e., shortening of the neck) may occur, are unknown and a cause for concern. Two recent systematic reviews demonstrated a high percentage of proximal type I endoleak rates (13% and 14%) after Ch-EVAR. It is far too early to be reassured about so-called disappearing early type I gutter endoleaks, as they may still pressurize the sac or reappear after years. Recently, presumed low-flow gutter-associated endoleaks after single renal chimney grafts became larger during follow-up and led to aneurysm rupture and death.
机译:我们感谢Donas博士和Wisselink博士对本文的评论,也感谢Donas博士为捍卫烟囱技术所做的努力。在有关评论,统计甚至是最后一篇文章中包含文章的细节上展开争斗是错误的。复查总是容易出现几个纳入偏倚,主要是为了避免患者的双重纳入。在他们自己的最新汇总分析中,他们包括了我们的两项研究,其中有一些重叠的患者队列。关于统计分析,可以在文献中为每种方法找到支持。其他作者之前也曾使用Fisher精确检验进行类似的比较。对读者而言,更重要的是在大多数患者中采用任何新技术之前,必须保持批判。在像芒斯特这样的专家中心里,毫无疑问的是,在为每个患者选择最合适的治疗方案之前,所有治疗方案(开放手术,有孔支架移植和烟囱技术)都经过精心平衡。但是,在每个演示文稿和出版物中都强调,经过精心选择的烟囱患者或没有其他治疗方案似乎更合适,这是每个专家中心的道德任务。我们祝贺多纳斯等人。他们最近的系列证明了Ch-EVAR在24个月的随访中的耐久性。但是,我们想指出的是,芒斯特大学采用开窗技术处理更复杂的案件(即需要超过1-2个烟囱),而上述文章中研究的40名患者仅占接受治疗的总患者的32%三年的观察期。正如Wisselink博士在他的邀请评论中所阐述的那样,I型“沟槽”内漏的长期结果,尤其是在可能发生动脉瘤疾病进展(例如,颈部缩短)的情况下,是未知的,值得关注。最近的两项系统评价表明,Ch-EVAR后近端I型内漏发生率较高(分别为13%和14%)。对于所谓的消失的早期I型沟内漏,要放心还为时过早,因为它们可能仍会加压囊或在多年后再次出现。最近,在随访期间,单个肾烟囱移植物之后的推测的低流量与沟槽相关的内漏变得更大,并导致动脉瘤破裂和死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号